Anti-obesity drug lowers heart-related problems

The weight-loss drug semaglutide is the first obesity treatment shown to help people live longer and have fewer cardiovascular problems. Developed as a drug for type 2 diabetes, semaglutide was first marketed as Ozempic; a higher-dose version for weight loss is called Wegovy. But because the drug is so popular, it can be hard to find, and it might not be covered by insurance.

Content restricted. Requires subscription